NCT03825367 2022-10-12Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AMLTherapeutic Advances in Childhood Leukemia ConsortiumPhase 1/2 Unknown13 enrolled
NCT02464657 2021-10-07Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)M.D. Anderson Cancer CenterPhase 1/2 Completed44 enrolled 12 charts